Provenzano M, Ikegami K, Bates K, Gaynor A, Hartman J, Jones A
J Clin Invest. 2025; 135(4).
PMID: 39836447
PMC: 11827844.
DOI: 10.1172/JCI185426.
Legare C, Berglund J, Duchesne E, Dumont N
Bioessays. 2024; 47(3):e202400216.
PMID: 39723693
PMC: 11848125.
DOI: 10.1002/bies.202400216.
Bohaczuk S, Amador Z, Li C, Mallory B, Swanson E, Ranchalis J
Genome Res. 2024; 34(12):2269-2278.
PMID: 39653420
PMC: 11694741.
DOI: 10.1101/gr.279747.124.
Annane D, Laberge L, Gallais B, Chevret S
Cochrane Database Syst Rev. 2024; 11:CD003218.
PMID: 39555632
PMC: 11571272.
DOI: 10.1002/14651858.CD003218.pub3.
Hartman J, Ikegami K, Provenzano M, Bates K, Butler A, Jones A
Ann Clin Transl Neurol. 2024; 11(12):3175-3191.
PMID: 39450929
PMC: 11651218.
DOI: 10.1002/acn3.52224.
Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1.
Hicks S, Frias J, Mishra S, Scotti M, Muscato D, Valero M
Mol Ther Nucleic Acids. 2024; 35(4):102338.
PMID: 39391766
PMC: 11465180.
DOI: 10.1016/j.omtn.2024.102338.
Quantum Chemical Characterization of Rotamerism in Thio-Michael Additions for Targeted Covalent Inhibitors.
Chaudhuri S, Rogers D, Hayes C, Inzani K, Hirst J
J Chem Inf Model. 2024; 64(19):7687-7697.
PMID: 39265068
PMC: 11480980.
DOI: 10.1021/acs.jcim.4c01379.
A familial, telomere-to-telomere reference for human mutation and recombination from a four-generation pedigree.
Porubsky D, Dashnow H, Sasani T, Logsdon G, Hallast P, Noyes M
bioRxiv. 2024; .
PMID: 39149261
PMC: 11326147.
DOI: 10.1101/2024.08.05.606142.
Rescue of Scn5a mis-splicing does not improve the structural and functional heart defects of a DM1 heart mouse model.
Nitschke L, Hu R, Miller A, Cooper T
Hum Mol Genet. 2024; 33(20):1789-1799.
PMID: 39126705
PMC: 11458005.
DOI: 10.1093/hmg/ddae117.
Changes in Physiopathological Markers in Myotonic Dystrophy Type 1 Skeletal Muscle: A 3-Year Follow-up Study.
Roussel M, Ravel-Chapuis A, Gobin J, Jasmin B, Leduc-Gaudet J, Gagnon C
J Neuromuscul Dis. 2024; 11(5):981-995.
PMID: 39031377
PMC: 11380274.
DOI: 10.3233/JND-230139.
Resolving the chromatin impact of mosaic variants with targeted Fiber-seq.
Bohaczuk S, Amador Z, Li C, Mallory B, Swanson E, Ranchalis J
bioRxiv. 2024; .
PMID: 39026856
PMC: 11257596.
DOI: 10.1101/2024.07.09.602608.
Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG).
Seifert B, Reddi H, Kang B, Bean L, Shealy A, Rose N
Genet Med. 2024; 26(8):101145.
PMID: 38836869
PMC: 11298302.
DOI: 10.1016/j.gim.2024.101145.
Disturbance of the human gut microbiota in patients with Myotonic Dystrophy type 1.
Mahdavi M, Prevost K, Balthazar P, Hus I, Duchesne E, Dumont N
Comput Struct Biotechnol J. 2024; 23:2097-2108.
PMID: 38803516
PMC: 11128782.
DOI: 10.1016/j.csbj.2024.05.009.
Myotonic dystrophy type 1 in South Korea: a comprehensive analysis of cancer and comorbidity risks.
Seo I, Park J
Neurol Sci. 2024; 45(9):4573-4581.
PMID: 38613590
DOI: 10.1007/s10072-024-07527-3.
Role of the repeat expansion size in predicting age of onset and severity in RFC1 disease.
Curro R, Dominik N, Facchini S, Vegezzi E, Sullivan R, Galassi Deforie V
Brain. 2024; 147(5):1887-1898.
PMID: 38193360
PMC: 11068103.
DOI: 10.1093/brain/awad436.
Advances in the discovery and analyses of human tandem repeats.
Chaisson M, Sulovari A, Valdmanis P, Miller D, Eichler E
Emerg Top Life Sci. 2023; 7(3):361-381.
PMID: 37905568
PMC: 10806765.
DOI: 10.1042/ETLS20230074.
Towards the Identification of Biomarkers for Muscle Function Improvement in Myotonic Dystrophy Type 1.
Aoussim A, Legare C, Roussel M, Madore A, Morissette M, Laprise C
J Neuromuscul Dis. 2023; 10(6):1041-1053.
PMID: 37694373
PMC: 10657677.
DOI: 10.3233/JND-221645.
Mitochondrial Dysfunction in Repeat Expansion Diseases.
Gimenez-Bejarano A, Alegre-Cortes E, Yakhine-Diop S, Gomez-Suaga P, Fuentes J
Antioxidants (Basel). 2023; 12(8).
PMID: 37627588
PMC: 10451345.
DOI: 10.3390/antiox12081593.
Clearance of defective muscle stem cells by senolytics restores myogenesis in myotonic dystrophy type 1.
Conte T, Duran-Bishop G, Orfi Z, Mokhtari I, Deprez A, Cote I
Nat Commun. 2023; 14(1):4033.
PMID: 37468473
PMC: 10356779.
DOI: 10.1038/s41467-023-39663-3.
Promising AAV.U7snRNAs vectors targeting improve DM1 hallmarks in patient-derived cell lines.
Almeida C, Robriquet F, Vetter T, Huang N, Neinast R, Hernandez-Rosario L
Front Cell Dev Biol. 2023; 11:1181040.
PMID: 37397246
PMC: 10309041.
DOI: 10.3389/fcell.2023.1181040.